Determination of Psychotropic Phenylalkylamine Derivatives in Biological Matrices by High-Performance Liquid Chromatography with Photodiode-Array Detection

Total Page:16

File Type:pdf, Size:1020Kb

Determination of Psychotropic Phenylalkylamine Derivatives in Biological Matrices by High-Performance Liquid Chromatography with Photodiode-Array Detection ;,,,,.,alo/ChromatograS93p(199_a_hy, 7-94 /k_)__¢_._ Elsevier Science Publishers B.V., Amsterdam CHROMSYMP. 2429 Determination of psychotropic phenylalkylamine derivatives in biological matrices by high-performance liquid chromatography with photodiode-array detection Hans-J6rg Helmlin and Rudolf Brenneisen* Instituteof Pharmacy, University of Berne, Baltzerstrasse 5, CH~3012 Berne (Switzerland) ABSTRACT Several procedures using high-performance liquid chromatography with photodiode-array detection have been developed to create phytochemical and toxicological profiles of phenylalkylamine derivatives in biological samples (e.g. plant materials and urine). Mesca- line-containing cactus samples were extracted with basic methanol, using methoxamine as internal standard; the extraction and clean- up of urine samples were performed on cation-exchange solid-phase extraction columns. The extracts were separated on a 3-#m ODS column with acetonitrile-water-phosphoric acid-hexylamine as the mobile phase. Peak detection was performed a_ 198 or 205 nm; peak identity and homogeneity were ascertained by on-line scanning of the UV spectra from 190 to 300 nm. The detection limit of phenylalkylamine derivatives in urine and cactus material was 0.026-0.056 #g/ml and 0.04 t_g/mg, respectively. Following a single oral dose of 1.7 mg/kg methylenedioxymethylamphetamine (MDMA) the concentrations found in urine ranged from 1.48 to 5.05 #gml MDMA and 0.07-0.90 #g/mi methylenedioxyamphetamine (a metabolite of MDMA). The mescaline content of the cactus Trichocereus ?achanoi varied between 1.09 and 23.75 #g/mg. INTRODUCTION South America, especially in the Andean regions and belongs, together with Lophophora williamsii Many natural and synthetic phenylalkylamine (Leto. ex Salm-Dyck) Coult. [4], to the mescaline- derivatives such as mescaline, amphetamine, meth- containing cactus species which are commercially ylamphetamine and 4-bromo-2,5-dimethoxyphen- available without legal restrictions in Switzerland ethylamine (see Table I) are known for their stim- and other European countries. ulant and/or hallucinogenic properties. Some very Considering the potential of abuse of phenyl- active ring-substituted amphetamines such as 3,4- alkylamine derivatives and mescaline-containing methylenedioxyamphetamine (MDA), 3,4-methyle- cactus species, it was the aim of this work to devel- nedioxymethylamphetamine (MDMA) and 3,4- op a selective, specific and sensitive analytical pro- methylenedioxyethylamphetamine (MDE) have cedureusinghigh-performanceliquidchromatogra- now appeared as "designer drugs" on the illicit pry with photodiode-array detection (HPLC- market, produced by clandestine laboratories [1]. DAD). This method should allow not only the iden- Owing to their high potential of abuse, most of tification of such compounds, but also the acquisi- these popular recreational substances are now in- tion ofphytochemical and pharmacokinetic profiles ternationally controlled. Despite this, MDMA in complex biological samples to estimate their toxi- I"Ecstasy", "XTC", "Adam") is used more fre- cological or therapeutic potency. The efficiency of quently as a controversial adjunct in psychotherapy HPLC-DAD in drug analysis, analytical toxicol- [2,3].Trichocereus pachanoi Britt. et Rose ("San Pe- ogy, forensic chemistry and phytochemistry of psy- dro") grows in subtropical and temperate areas of chotropic drugs has been shown previously [5-18]. 0021-9673/92/$05.00 (O, 1992 Elsevier Science Publishers B.V. All rights reserved 88 H.-J. HELMLIN, R. BRENNEISEN "[_ TABLE I & -_._'_ STRUCTURES OF PHENYLALKYLAMINE DERIVATIVES I s,",'_ Structure Peak no. Compound [[__ NHa I Amphetamine t 2 3,4-Methylenedioxyamphetamine (MDA) ._/_ ! L_[[t'_YA_ N _ 3 Methylamphetamine '3 s 4 4 4-Methoxyamphetamine '" H.,,CO' v [_"'_ NHa 5 Phentermine ) [J_ [ 6 3,4-Methylenedioxymethamphetamine (MDMA) °X..o/ ! CH30 i__ _,__ A. T NHa 7 5-Methoxy-3,4-methylenedioxyamphetamine (MMDA) ' H3COi_NH2 8 3,4,5-Trimethoxyamphetamine H3CO' T t OCH3 H I ' 9 3,4-Methylenedioxyethylamphetamine(MDE) ! HaCO j_NHa 10 2,5-Dimethoxyamphetamine '_ ["'_ /_"' 'OCH3 11 4-Bromo-2,5-dimethoxyphenylethylamine (DOBP,2-CB) HaCOj._/-_jNH2 Br" '"'cf -OCH3 H3CO j_NHa 12 2,5-Dimethoxy-4-methylamphetamine (DOM,STP) /' _ 'OCH_ · (Continued on p. 89) 4 LENNEISEN HPLC OF PHENYLALKYLAMINE DERIVATIVES 89 TABLE ] (continued) Structure PeakNo. Compound I H3C_ [_NH2 13 4-Bromo-2,5-dimethoxyamphetamine (DOB) '14 2,5-Dimethoxy-4-ethylamphetamine (DOET) V _ 'OCH3 15 Mescaline H3CO i_ ''._N H2 H_C0' T I., OH OCH3'1" H3CO _NH2I,_,II 16 Methoxamine v 'OCH3 } EXPERIMENTAL through a membrane filter (regenerated cellulose, 0.45 #m, Schleicher and Schuell) and degassed by Instrumentation sonication and during use with a constant flow of The HPLC-DAD system consisted of a Hewlett- helium. Methanol was used for washing the col- 0 Packard1090Mliquidchromatograph(Hewlett- umn. Packard, Waldbronn, Germany), an HP 1090L au- The separation of urine samples containing tosampler, an HP 1040M photodiode~array detec- MDMA and MDMA metabolites was performed _IMDA) tor, an HP 79994A Chemstation (software version isocratically at 40°C on a 125 x 4.0 I.D. column 1.05),an HP 7470A x/y plotter and an HP 2225A packed with 3-$tm Spherisorb ODS-1. The mobile Thinkjet printer, phase was acetonitrile-water (72:928, v/v; 57:943, w/w), containing 5.0 ml (8.5 g) orthophosphoric Chromatographic conditions acid (85%) and 0.28 ml (0.22 g) hexylamine per The separation of fourteen phenylalkylamine de- 1000 ml. The flow-rate was 0.8 mi/min. rivatives was performed at 40°C on a 125 x 4.0 mm The separation of the cactus samples was per- I.D. column packed with 3-tim Spherisorb ODS-1 formed isocratically at 25°C on a 150 x 4.6 mm (Phase Separations), filled by Stagroma (Wallisel- I.D. column with a 20 x 4.0 mm I.D. precolumn, len, Switzerland). The solvent gradient was devel- packed with 3-ttm Spherisorb ODS-1. The mobile oped by using the CARTAGO (computer assisted phase was acetonitrile-water (108:892, v/v), con- retention time prediction and gradient optimiza- taining 5.0 ml (8.5 g) orthophosphoric acid (85%) tion) software; details of this procedure are publish- and 0.28 mi (0.22 g) hexylamine per 1000 ml. The ed elsewhere [19,20]. Solvent A was water contain- flow-rate was I ml/min. ing 5.0 ml (8.5 g) orthophosphoric acid (85%) and BP,2-CB) 0.28 ml (0.22 g) hexylamine per 1000 mi; solvent B Chemicals and reagents was acetonitrile containing 100 mi water, 5.0 ml (8.5 Amphetamine sulphate was obtained from Sieg- g) orthophosphoric acid (85%) and 0.28 mi (0.22 g) fried (Zofingen, Switzerland) and methylampheta- _TP) hexylamineper 1000 ml. The gradient profile was as mine hydrochloride from Dr. Grogg Chemie follows: 0_10.6 min, 5.5% B in A (isocratic); 10.6- (Berne, Switzerland). Mescaline hydrochloride was 21.6 min, 5.5-39% B in A (linear gradient). The supplied by Laboratoires Plan (Geneva, Switzer- !inuedonp.89) flow-rate was 0.8 mi/min. The eluent was filtered land), methoxamine hydrochloride and MDA were 90 H.-J. HELMLIN, R. BRENNEISEN 'l provided by Sigma (St. Louis, MO, USA). MDMA, x 0.5 mi of methanol-hydrochloric acid (7.3%; ,._ MDE, 5-methoxy-3,4-methylenedioxyampheta- 97.5:2.5) at a flow-rate of about 0.5 ml/min. Ali- mine (MMDA), 4-methoxyamphetamine, 2,5-di- quots of 10 #1 of the defined volume of the eluates methoxyamphetamine, 2,5-dimethoxy-4-methylam- were injected into the HPLC-DAD system for the 5 phetamine (DOM,STP), 2,5-dimethoxy-4-ethylam- determination of MDMA and MDA. For !ow phetamine (DOET), 3,4,5-trimethoxyampheta- MDMA and MDA levels a concentration stepmay mine, 4-bromo-2,5-dimethoxyamphetamine (DOB) be necessary. An aliquot of 1.5 ml ofthe eluates was and phentermine were donated by the Division of added to 68 #1 of I M KeHPO4, concentrated to ":; Narcotic Drugs, United Nations (Vienna, Austria). about 100 #1 under a stream of nitrogen and recon- 4-Bromo-2,5-dimethoxyphenethylamine (DOBP,2- stituted to 150.0 #1 with methanol-water (50:50). _ CB) was a gift of the Swiss Association for Psycho- The resulting solution, with a pH of about 4-5, was lyric Therapy. All other chemicals and reagents then sonicated for 2 min and filtered through the tip ';7, were of HPLC or analytical-reagent grade and were of a Pasteur pipette filled with cotton wool. Aliqu- , purchased from Merck (Darmstadt, Germany) or ots of 10/al were used for determination by HPLC- Fluka(Buchs,Switzerland). DAD. The cactus samples were cut in half, lyophilized ._ Urine and cactus samples and stored in a desiccator under vacuum and pro- The urine samples were obtained from patients tected from light until used for analysis. A repre- treated with MDMA by psychiatrists of the Swiss sentative sample of the cactus specimen was pulver- Association for Psycholytic Therapy. Urine sam- ized with a grinder. An accurately weighed amount pies were collected approximately 6 h after the ad- of the powdered sample (about l0 mg) was then ministration of 1.7 mg/kg MDMA. The specimens washed four times with 1 mi of diethyl ether by so- of Trichocereus pachanoi Britt. et Rose and Lo- nication (5 min) and filtration through a 0.2-#m re- phophora diffusa (Croizat) Bravo (Cactaceae) were generated cellulose filter (Spartan 13/30, Schleicher bought at flower shops and shopping centres in & Schuell). The defatted sample was extracted four Switzerland, or obtained from private collections, times with 0.5 ml of methanol-ammonia (33%; 99:1), containing 150.0 #g/ml methoxamine hydro- ., Sample preparation chloride as internal standard (I.S.), by sonication (5 The extraction and clean-up of urine samples min) and filtration through a 0.2-#m regenerated , (real, spiked, blank) were carried out on Adsorbex cellulose filter.
Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • The Role of Norepinephrine in the Pharmacology of 3,4
    !"#$%&'#$&($)&*#+,-#+"*,-#$,-$."#$/"0*102&'&34$&($ 56789#."4'#-#:,&;41#."01+"#.01,-#$<9=9>6$?#[email protected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`,E#-E$ I0--$ D-.#*$ 2*#0.,J#2&11&-@X&*3a',2#-2#@aY48-28 -:aSX]a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
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • A Pharmacological. Study of the Ephedrine Isomers
    This dissertation has been 64—1295 microfilmed exactly as received PATIL, Popat Narayan, 1934- A PHARMACOLOGICAL. STUDY OF THE EPHEDRINE ISOMERS. The Ohio State Universityt Ph,Dt, 1963 Pharmacology University Microfilms, Inc., Ann Arbor, Michigan A PHARMACOLOGICAL STUDY OF THE HPHEDRIHE ISOMERS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Popat Narayan Patil, B. Sc. in Phara., M. Sc. xxxxx The Ohio S tate University 1963 Approved by Adi College of Pharmacy ACKNOWLEDGMENTS The author would Ilka to acknowledge the efforte of Drs. Arthur Tye and Jules B. LaPidus for their valuable advice and Inspiration. The suggestions of Drs* Harold H. Wolf and John W. Nelson are also acknowledged. Special thanks to Mr* Balkrishna Modi for preparing the isomers and Mr. Dalai for the statistical analysis of the data* ii TABLE OF CONTENTS ACKNOWLEDGMENTS .................................................................................. LIST OF TABLES.................................................................................. LIST OF ILLUSTRATIONS ...................................................................... LIST OF ABBREVIATIONS ...................................................................... CHAPTER I. INTRODUCTION AND LITEiiATURS REVIEW G e n e r a l ......................................... .................................... Literature on Optical Isom ers ................................. II. MATERIALS AND METHODS Acute
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • The Inhibition of Noradrenaline Uptake by Sympathomimetic Amines in the Rat Isolated Heart
    Brit. J. Pharmacol. (1965), 25. 34-49. THE INHIBITION OF NORADRENALINE UPTAKE BY SYMPATHOMIMETIC AMINES IN THE RAT ISOLATED HEART BY A. S. V. BURGEN AND L. L. IVERSEN From the Department ofPharmacology, University of Cambridge (Received August 30, 1964) -In the rat isolated heart, noradrenaline can be accumulated by two distinct processes. The first process (Uptake1) is half saturated at a (±)-noradrenaline concentration of 0.11 pg/ml. and continues to operate at external noradrenaline concentrations up to 1 ,ug/ml. (Iversen, 1963). The second process comes into play at slightly higher concentra- tions and becomes half saturated at 42.6 ,ug/ml. (Iversen, 1965b). Both of these processes act also upon adrenaline, which competes for uptake when noradrenaline is also present (Iversen, 1965a, b). It seems probable, therefore, that other sympathomimetic amines would have an affinity for the systems operative in accumulation, and indeed, there is some evidence in the literature that amphetamine, tyramine and ephedrine inhibit noradrenaline uptake (Dengler, Spiegel & Titus, 1961; Axelrod & Tomchick, 1960). This paper is concerned with the measurement of the affinity of sympathomimetic amines for the uptake system as measured by inhibition of noradrenaline accumulation. Needless to say, the demonstration that a substance inhibits noradrenaline uptake does not prove that it is also transported by the system; this would require a direct measurement of the accumulation of the substance in the tissue. A preliminary account of some of these results has already been published (Iversen, 1964). METHODS Inhibition of UptakeL In control experiments, hearts were perfused with a medium containing (±)-[_4C]noradrenaline (Nichem Inc., Bethesda, Maryland, U.S.A.) at a concentration of 10 ng/ml.
    [Show full text]
  • The Effects of Adrenaline and Other Drugs Affecting Carbohydrate Metabolism on Contractions of the Rat Diaphragm
    Brit. J. Pharmacol. (1964), 23, 184-200. THE EFFECTS OF ADRENALINE AND OTHER DRUGS AFFECTING CARBOHYDRATE METABOLISM ON CONTRACTIONS OF THE RAT DIAPHRAGM BY W. C. BOWMAN AND C. RAPER From the Department of Pharmacology, School of Pharmacy, University of London, Brunswick Square, London, W.C.1 (Received March 18, 1964) The ability of several drugs to restore directly elicited twitches of the rat diaphragm depressed by excess potassium chloride has been studied. The drugs found to be effective were sympathomimetic amines, insulin, glucagon, caffeine, theophylline, calcium chloride and hexosephosphates. The effects of the sympathomimetic amines and glucagon were blocked by P-receptor blocking agents. Phloridzin blocked the effect of insulin and depressed that of glucagon. The increase in twitch tension still occurred under anaerobic conditions and was not abolished by the glycolytic inhibitor, iodoacetate. All of the effective drugs are known to affect carbohydrate metabolism and the suggestion by Ellis (1955) that the effect on contractions may be a result of increased intracellular hexosephosphate levels is discussed. Adrenaline and some other sympathomimetic amines have long been known to cause an increase in the contractions of fast-contracting skeletal muscles, stimulated directly or through their motor nerves (see Bowman, Goldberg & Raper, 1962, for references). The mechanism underlying this potentiation is unknown, but Ellis, Davis & Anderson (1955) demonstrated that the relative potencies of a series of sympathomimetic amines in potentiating the contractions of the isolated diaphragm muscle of the rat and in stimulating glycogenolysis in this tissue were similar, suggesting that the two effects might be interrelated. Ellis & Beckett (1954) had previously shown on the same tissue that adrenaline retained its twitch-potentiating effect under anaerobic conditions and in the presence of the glycolytic inhibitor, iodoacetate.
    [Show full text]
  • Electronic Supplementary Material (ESI) for Analytical Methods
    Electronic Supplementary Material (ESI) for Analytical Methods. This journal is © The Royal Society of Chemistry 2021 Supplemental Table 1. List of substances with corresponding elemental composition, exact mass, retention time (RT), minimum screening sensitivity, extraction recovery and the shifts of mass and retention time from three-day validation analysis. Minimum [M+H]+ Mass RT RT Elemental Screening Extraction Substances Exact Shift shift Composition Sensitivity Recovery mass (ppm) (min) (s) (ng/mL) 1,3-Benzodioxolyl-N-methylbutanamine C12H17NO2 208.1332 0.1 3.13 0.8 0.50 96.6% 15β-Hydroxytestosterone C19H28O3 305.2111 -1.1 3.50 -0.3 0.10 87.5% 16β-Hydroxytestoterone C19H28O3 305.2111 -1.1 3.97 0.1 0.25 94.8% 2-(1-Hydroxyethyl) promazine sulfoxide C19H24N2O2S 345.1631 -1.3 3.13 0.5 1.00 41.1% 2-(1-Hydroxypropyl)promazine sulfoxide C20H26N2O2S 359.1788 -1.1 3.35 0.9 2.00 38.5% 2-Aminoheptane C7H17N 116.1434 0.0 2.98 0.1 ND1 89.1% 2α-Hydroxymethylethisterone C22H30O3 343.2268 -1.8 4.35 -0.2 0.25 96.8% 3,4-Methylenedioxyamphetamine C10H13NO2 180.1019 0.1 2.78 0.0 0.50 73.8% 3,4-Methylenedioxypropylamphetamine C13H19NO2 222.1489 -0.9 3.14 0.3 0.10 113.1% 3-Hydroxymepivacaine C15H22N2O2 263.1754 -0.3 2.52 -0.6 0.20 89.2% 3-Hydroxypromazine C17H20N2OS 301.1369 -0.7 3.60 -2.0 0.10 77.9% 3-OH Lidocaine C14H22N2O2 251.1754 1.1 2.42 0.5 0.06 92.4% 4-Chloroamphetamine C9H12ClN 170.0731 0.1 3.27 0.2 ND 91.8% 4-Hydroxypropranolol C16H21NO3 276.1594 -0.7 3.17 2.7 0.20 83.7% 4-Methoxymethamphetamine C11H17NO 180.1383 -0.4 2.96 0.0 0.05 72.7% 5,6-Methylenedioxy-2-aminoindane
    [Show full text]
  • SOFT 2014 Meeting Abstracts.Pdf
    Abstracts Of Platform Presentations S-01 Urinary Markers for AB-FUBINACA Intake Determined by Human Hepatocytes Incubation and High- Resolution Mass Spectrometry Marisol S. Castaneto*1,2, Ariane Wohlfarth1, Shaokun Pang3, Mingshe Zhu4, Karl B. Scheidweiler1 and Marilyn A. Huestis1; 1Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; 2Program in Toxicology, University of Maryland Baltimore, Baltimore, MD, USA; 3Department of Biotransformation, Bristol-Myers Squibb Research and Development, Princeton, NJ, USA; 4AB SCIEX, Foster City, CA, USA Introduction: Synthetic cannabinoids (SC) intake increased worldwide, with purported psychotropic effects documented in drug user blogs, poison control call centers, driving under the influence of drugs, and emergency room visits. Although multiple SC classes are now DEA controlled, new cannabimimetic compounds continue to emerge. It is critically important to identify urinary SC targets to document SC intake, to link adverse effects with specific SC, and to educate the public on the dangers of designer drug use. Recently, our laboratory conducted metabolite-profiling studies of SC with human hepatocytes incubation, high resolution mass spectrometry (HRMS), and data-mining software. AB-FUBINACA, N-(1-amino-3-methyl-1-oxabutan-2-yl)-1-(4- fluorobenzyl)-1H-indazole-3-carboxamide, is a scheduled indazole derivative SC originally identified in Japanese seized herbal products with unknown human pharmacology (CB1 Ki = 0.9 nM). Objective: Our goal was to characterize AB-FUBINACA’s metabolism with human hepatocytes incubation and HRMS to identify the best urinary targets. Method: We incubated 10 µM AB-FUBINACA in pooled cryopreserved human hepatocytes at 37oC for 0 (control), 1, and 3 h.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Epinephrine, Phenylephrine, and Methoxamine Induce Infiltrative
    Acta Pharmacologica Sinica (2009) 30: 1227–1236 npg © 2009 CPS and SIMM All rights reserved 1671-4083/09 $32.00 www.nature.com/aps Original Article Epinephrine, phenylephrine, and methoxamine induce infiltrative anesthesia via α1-adrenoceptors in rats Ja-ping SHIEH1, Chin-chen CHU1, Jhi-joung WANG1, 2, Mao-tsun LIN2, * 1Department of Anesthesiology and 2Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan, China Aim: To assess whether epinephrine, phenylephrine, and methoxamine act via certain subtypes of adrenoceptors to exert their local anesthetic activity. Methods: We investigated cutaneous anesthesia from adrenoceptor agonists and/or antagonists in conscious, unanesthetized Sprague-Dawley male rats (weight 200−250 g). Cutaneous anesthesia was evidenced by a block of the cutaneous trunci muscle reflex, which is characterized by reflex movement of the skin over the back produced by twitches of lateral thoracispinal muscles in response to local dorsal cutaneous noxious pinprick. Results: Local infiltration of epinephrine,L -phenylephrine, or methoxamine alone induces cutaneous anesthesia in rats in a dose- dependent way. Epinephrine is found to be 19 and 29 times more potent than those of methoxamine and L-phenylephrine, respectively. The cutaneous anesthesia induced by epinephrine, phenylephrine, or methoxamine can be significantly reduced by α1-adrenoceptor antagonists (eg, prazosin), α1, α2-adrenoceptor antagonist, α1A-adrenoceptor antagonist (eg, 5-methylurapdil), α1B- adrenoceptor antagonist (eg, chloroethylclonidine),
    [Show full text]